Do we need to use the same type of ART regimens in an HIV-infected patient with a viral load of 550,000 HIV RNA copies/mL and a CD4 cell count of 75 cells/µL than in a patient who has been virologically suppressed for 7 years and has a current CD4 cell count of 750 cells/µL? Can we ‘simplify’ the ART regimen in virologically suppressed patients? These questions have been a matter of research and controversy during the last two decades. Since at the present moment HIV infection needs to be treated for the entire life of the patient there is a strong motivation to use ART regimens that are as simple, efficacious and safe as possible. Numerous clinical trials have evaluated ART simplification in virologically suppressed patients. In many occasions, the new ‘simple’ regimens have been very different from the regimens used in antiretroviral naïve patients with active viral replication. There have been multiple attempts to use regimens with less than three antiretroviral drugs: monotherapy with boosted protease inhibitors, dual therapy completely sparing nucleoside reverse transcriptase inhibitors (NRTIs), dual therapy sparing just one NRTI and dual therapy sparing both NRTIs and boosted protease inhibitors. In many occasions, results of these trials have produced unexpectedly disappointing results. For example, it is still unclear why potent ART regimens combining a boosted protease inhibitor and an integrase inhibitor have underperformed compared to triple therapy regimens that include two NRTIs. Even if the new simple regimen includes three antiretroviral drugs there have been unexpected failures in clinical trials when the issues of archived mutations or duration of virologically suppression have not been taken into account. Based on the results of all these clinical trials we have learnt that the success ART simplification is determined by critical pharmacological, biological and behavioural factors such as potency and the genetic barrier of the new regimen, the presence of archived mutations, duration of virological suppression and patient’s pattern of adherence. With the advent of long-acting antiretrovirals and broadly neutralising antibodies, the interest in ART simplification has been renewed because we now have the types of drugs that would theoretically permit for the first time in HIV therapeutics the use of regimens that do not involve daily dosing of antiretrovirals.